{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:57:14Z","timestamp":1781539034329,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s11095-026-04093-5","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T19:11:39Z","timestamp":1778008299000},"page":"1655-1664","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Cell-Based Reporter Gene Assay for TNF-\u03b1 Neutralization: Analytical Qualification and Application to Adalimumab and Its Biosimilars"],"prefix":"10.1007","volume":"43","author":[{"given":"Christelle Anne F.","family":"Ancajas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7859-0843","authenticated-orcid":false,"given":"Baolin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"issue":"9","key":"4093_CR1","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/nrd1182","volume":"2","author":"B Bain","year":"2003","unstructured":"Bain B, Brazil M. Adalimumab. Nat Rev Drug Discov. 2003;2(9):693\u20134.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"4093_CR2","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41573-024-01053-9","volume":"23","author":"M Croft","year":"2024","unstructured":"Croft M, Salek-Ardakani S, Ware CF. Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer. Nat Rev Drug Discov. 2024;23(12):939\u201361.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"4093_CR3","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s12325-019-01145-8","volume":"37","author":"GR Burmester","year":"2020","unstructured":"Burmester GR, Gordon KB, Rosenbaum JT, Arikan D, Lau WL, Li P, et al. Long-term safety of adalimumab in 29,967 adult patients from global clinical trials across multiple indications: an updated analysis. Adv Ther. 2020;37(1):364\u201380.","journal-title":"Adv Ther"},{"key":"4093_CR4","doi-asserted-by":"crossref","unstructured":"Lu X, Hu R, Peng L, Liu M, Sun Z. Efficacy and safety of adalimumab biosimilars: current critical clinical data in rheumatoid arthritis. Front Immunol. 2021;12.","DOI":"10.3389\/fimmu.2021.638444"},{"issue":"1","key":"4093_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s40744-020-00259-8","volume":"8","author":"TWJ Huizinga","year":"2021","unstructured":"Huizinga TWJ, Torii Y, Muniz R. Adalimumab biosimilars in the treatment of rheumatoid arthritis: a systematic review of the evidence for biosimilarity. Rheumatol Ther. 2021;8(1):41\u201361.","journal-title":"Rheumatol Ther"},{"key":"4093_CR6","doi-asserted-by":"crossref","unstructured":"Ascef BdO, Almeida MO, Medeiros-Ribeiro ACd, Oliveira de Andrade DC, Oliveira Junior HAd, de So\u00e1rez PC. Therapeutic equivalence of biosimilar and reference biologic drugs in rheumatoid arthritis: a systematic review and meta-analysis. JAMA Network Open. 2023;6(5):e2315872-e.","DOI":"10.1001\/jamanetworkopen.2023.15872"},{"issue":"11","key":"4093_CR7","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0117","volume":"12","author":"V Abitbol","year":"2023","unstructured":"Abitbol V, Benkhalifa S, Habauzit C, Marotte H. Navigating adalimumab biosimilars: an expert opinion. J Comp Eff Res. 2023;12(11):e230117.","journal-title":"J Comp Eff Res"},{"issue":"5","key":"4093_CR8","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1007\/s12325-024-02818-9","volume":"41","author":"JR Allegretti","year":"2024","unstructured":"Allegretti JR, Brady JH, Wicker A, Latymer M, Wells A. Relevance of adalimumab product attributes to patient experience in the biosimilar era: a narrative review. Adv Ther. 2024;41(5):1775\u201394.","journal-title":"Adv Ther"},{"issue":"1","key":"4093_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2551208","volume":"17","author":"D Baldisseri","year":"2025","unstructured":"Baldisseri D, Luo S, Ancajas CAF, Ortega-Rodriguez U, Fischer C, Zou G, et al. NMR-based structural integrity analysis of therapeutic monoclonal antibodies: a comparative study of Humira and its biosimilars. mAbs. 2025;17(1):2551208.","journal-title":"mAbs"},{"key":"4093_CR10","unstructured":"U.S. Food and Drug Administration Draft Guidance for Industry. Development of therapeutic protein biosimilars: comparative analytical assessment and other quality-related considerations. 2019. Available from\u00a0https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-issues-draft-guidance-industry-design-and-evaluation-comparative-analytical-studies."},{"key":"4093_CR11","doi-asserted-by":"crossref","unstructured":"Nupur N, Joshi S, Gulliarme D, Rathore AS. Analytical similarity assessment of biosimilars: global regulatory landscape, recent studies and major advancements in orthogonal platforms. Front Bioeng Biotechnol. 2022;10.","DOI":"10.3389\/fbioe.2022.832059"},{"issue":"8","key":"4093_CR12","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s12325-019-00979-6","volume":"36","author":"R Markus","year":"2019","unstructured":"Markus R, McBride HJ, Ramchandani M, Chow V, Liu J, Mytych D, et al. A review of the totality of evidence supporting the development of the first adalimumab biosimilar ABP 501. Adv Ther. 2019;36(8):1833\u201350.","journal-title":"Adv Ther"},{"key":"4093_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2023.115543","volume":"234","author":"S Mill\u00e1n-Mart\u00edn","year":"2023","unstructured":"Mill\u00e1n-Mart\u00edn S, Jakes C, Carillo S, Bones J. Multi-attribute method (MAM) to assess analytical comparability of adalimumab biosimilars. J Pharm Biomed Anal. 2023;234:115543.","journal-title":"J Pharm Biomed Anal"},{"issue":"4","key":"4093_CR14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40268-023-00437-3","volume":"23","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Arora T, Klakamp S, Davis J, Chandrasekher YA, Young G, et al. Demonstration of physicochemical and functional similarity of biosimilar adalimumab-aqvh to adalimumab. Drugs R D. 2023;23(4):377\u201395.","journal-title":"Drugs R D"},{"key":"4093_CR15","doi-asserted-by":"crossref","unstructured":"Wadhwa M, Bird C, Atkinson E, Cludts I, Rigsby P. The first WHO international standard for adalimumab: dual role in bioactivity and therapeutic drug monitoring. Front Immunol. 2021;12.","DOI":"10.3389\/fimmu.2021.636420"},{"key":"4093_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jpba.2018.03.057","volume":"155","author":"R Camacho-Sandoval","year":"2018","unstructured":"Camacho-Sandoval R, Sosa-Grande EN, Gonz\u00e1lez-Gonz\u00e1lez E, Tenorio-Calvo A, L\u00f3pez-Morales CA, Velasco-Vel\u00e1zquez M, et al. Development and validation of a bioassay to evaluate binding of adalimumab to cell membrane-anchored TNF\u03b1 using flow cytometry detection. J Pharm Biomed Anal. 2018;155:235\u201340.","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"4093_CR17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0165-2478(95)00026-2","volume":"46","author":"KSA Khabar","year":"1995","unstructured":"Khabar KSA, Siddiqui S, Armstrong JA. WEHI-13VAR: a stable and sensitive variant of WEHI 164 clone 13 fibrosarcoma for tumor necrosis factor bioassay. Immunol Lett. 1995;46(1):107\u201310.","journal-title":"Immunol Lett"},{"issue":"2","key":"4093_CR18","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.leukres.2010.07.040","volume":"35","author":"L Minafra","year":"2011","unstructured":"Minafra L, Di Cara G, Albanese NN, Cancemi P. Proteomic differentiation pattern in the U937 cell line. Leuk Res. 2011;35(2):226\u201336.","journal-title":"Leuk Res"},{"issue":"2","key":"4093_CR19","first-page":"87","volume":"8","author":"JD Twomey","year":"2025","unstructured":"Twomey JD, George S, Zhang B. Fc gamma receptor polymorphisms in antibody therapy: implications for bioassay development to enhance product quality. Antib Ther. 2025;8(2):87\u201398.","journal-title":"Antib Ther"},{"key":"4093_CR20","unstructured":"USP \u23291032\u232a Design and Development of Biological Assays. In USP-NF. Rockville, MD: United States Pharmacopeia. https:\/\/doi.usp.org\/USPNF\/USPNF_M1354_01_01.html."},{"key":"4093_CR21","unstructured":"USP <1034> Analysis of Biological Assays. In USP-NF. Rockville, MD: United States Pharmacopeia. https:\/\/doi.usp.org\/USPNF\/USPNF_M5677_01_01.html."},{"key":"4093_CR22","unstructured":"International Conference on Harmonization (ICH) guidelines Q2(R2). Validation of analytical procedures, March 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/q2r2-validation-analytical-procedures. Accessed 7 Oct 2024."}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04093-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04093-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04093-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:30:55Z","timestamp":1781537455000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04093-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4093"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04093-5","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The views expressed in this article are those of the authors and are based on experimental data and a review of relevant scientific literature. These views should not be construed to represent FDA\u2019s views or policies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Disclaimer"}},{"value":"No potential conflicts of interest were disclosed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}